South Korean firm CELSET launches SOLTOX botulinum toxin globally
Biotech company CELSET INC. has introduced SOLTOX, a type A botulinum toxin, to the international medical aesthetics market.
South Korean biotechnology company CELSET INC. has launched its medical aesthetic product line, SOLTOX, targeting international markets. The product, a type A botulinum toxin, represents the company's effort to expand its footprint within the global cosmetic injectable industry.
The international release follows the company’s domestic development and production efforts in South Korea. CELSET aims to establish SOLTOX as a viable alternative for practitioners in a sector currently dominated by a few major global pharmaceutical entities.
Market analysts note that the botulinum toxin market is highly competitive, requiring rigorous regulatory adherence and supply chain management. CELSET's success will depend on its ability to secure regional distribution partners and satisfy the specific safety standards required in various international jurisdictions.